Physician profile
Larry Schlabach
NPI 1386609394
$382.85
in general payments reported to CMS, 2019-2025
12 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.92 · 2021: $87.75 · 2022: $15.70 · 2023: $35.85 · 2024: $75.79 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.48 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $103.05 | 2023-2025 | |
| Abbvie INC. | $75.83 | 2021 | |
| Gilead Sciences, INC. | $38.24 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $29.89 | 2025 | Enhertu |
| Shire North American Group INC | $24.62 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Pfizer INC. | $20.53 | 2025 | |
| Glaxosmithkline, LLC. | $19.98 | 2025 | Blenrep |
| Celgene Corporation | $19.71 | 2024 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2022 | |
| Merck Sharp & Dohme LLC | $14.30 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Schlabach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.